Short description
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
Description
ITeos Therapeutics is a private biotechnology company targeting the metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology, therapeutic cancer vaccines, cancer biology, and translational medicine in cancer.
iTeos endeavors to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies).
Last funding
Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Cambridge, Massachusetts, United States, North America
Founded on
January 1, 2011
Exited on
July 23, 2020
Went public on
July 23, 2020
Stock symbol
ITOS
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$56378 - 90123
Sign in for full access
Investors
No Way, Noaccessforu, Uh Ohhhh, Noaccess, Noaccessforu, Noaccess, Noaccessforu, Noaccess, Noaccess, Cannot Access, Cannot Access, Nopepepe, Blurry Noaccess, Blurry Noaccess, Cannot Access, No Way, Uh Ohhhh
Sign in for full access
Founders
Benoît Van den Eynde, Michel Detheux